Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Delcath Systems, Inc.    

DELCATH SYSTEMS, INC.
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsCalendarCompanyFinancials 
Company
Delcath Systems, Inc. is a pharmaceutical and medical device company which focuses on oncology and liver cancer therapy.It develops and commercializes Melphalan Hydrochloride for Injection which is a proprietary product for use with the Delcath Hepatic Delivery System.The company was founded in... 
More about the company
Latest news on DELCATH SYSTEMS, INC.
02/12DELCATH SYSTEMS, INC. (NASDAQ : DCTH) Files An 8-K Other Events
AQ
02/12DELCATH SYSTEMS, INC. : Other Events (form 8-K)
AQ
02/02Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe
GL
02/01Delcath Announces Satisfaction of 2016 Convertible Note
GL
01/26DELCATH SYSTEMS, INC. (NASDAQ : DCTH) Files An 8-K Other Events
AQ
01/26DELCATH SYSTEMS, INC. : Other Events (form 8-K)
AQ
01/11DELCATH : Announces Special Protocol Agreement Modification With FDA
AQ
01/10Delcath Announces Special Protocol Agreement Modification With FDA
GL
01/09Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Publishe..
GL
2017DELCATH : Announces Exit from Convertible Note
AQ
More news
Sector news : Medical Prosthetics
02/15STRYKER : U.S. Regulators Extend Window for Critical Stroke Treatment
DJ
02/15STRAUMANN : margin outlook takes shine off revenue surge
RE
02/15COLOPLAST A/S : ConvaTec beats low full-year expectations, shares rise
RE
02/07ESSILOR INTERNATIONAL : Makes Changes to Board of Directors
DJ
02/06BECTON DICKINSON AND : Revenue Helped by Life-Sciences -- Earnings Review
DJ
More sector news : Medical Prosthetics
News from SeekingAlpha
02/02Delcath announces 500th Chemostat procedure in Europe 
2017Delcath updates on convertible note agreement 
20172017 YTD worst losers - healthcare 
2017YOUR DAILY PHARMA SCOOP : Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA A.. 
2017DELCATH SYSTEMS INC NEW reports Q3 results 
Chart DELCATH SYSTEMS, INC.
Duration : Period :
Delcath Systems, Inc. Technical Analysis Chart | US24661P5008 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Jennifer K. Simpson President, Chief Executive Officer & Director
Roger G. Stoll Non-Executive Chairman
John Purpura Executive Vice President-Global Operations
Barbra C. Keck Secretary, Chief Financial & Accounting Officer
William Dodge Rueckert Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DELCATH SYSTEMS, INC.-91.09%6
STRAUMANN HOLDING-3.41%11 486
SONOVA HOLDING-3.52%10 435
COCHLEAR LIMITED1.79%8 000
INSULET CORPORATION11.23%4 466
DENTIUM CO LTD--.--%717